SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
| Valuation | |
|---|---|
| Market Cap ($M) | 12.59 |
| Enterprise Value ($M) | 14.63 |
| Book Value ($M) | -2.18 |
| Book Value / Share | -0.04 |
| Price / Book | -5.79 |
| NCAV ($M) | -9.83 |
| NCAV / Share | -0.17 |
| Price / NCAV | -1.28 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -4.19 |
| Return on Assets (ROA) | -2.76 |
| Return on Equity (ROE) | n/a |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 1.05 |
| Current Ratio | 1.05 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 10.23 |
| Assets | 10.93 |
| Liabilities | 20.06 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G | Armistice Capital, Llc | 9.99 | ||
| 13G/A | Nantahala Capital Management, LLC | 1.50 | -98.02 | |
| 13D/A | Hanmi Pharmaceutical Co., Ltd. | 22.17 | 238.11 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 150,865 | 723,484 | 20.85 | |
| 170,925 | 615,581 | 27.77 | |
| 258,905 | 878,492 | 29.47 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| ANIX – Anixa Biosciences, Inc. | APM – Aptorum Group Limited |
| APRE – Aprea Therapeutics, Inc. | APVO – Aptevo Therapeutics Inc. |
| ARTL – Artelo Biosciences, Inc. |
Financial data and stock pages provided by
Fintel.io